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The vascular and parenchymal myloid deposits in Alzheimer disease (AD), normal aging and Down syndrome are main- 
ly composed of a 4 kDa polypeptide (A4), which derives from a larger precursor protein (APP). There is evidence that 
APP is a transmembrane glycoprotein present in most tissues, but the characteristics of APP in intact cells are not yet 
known. In order to investigate his issue, we examined the immunoreactivity of fibroblasts of human and nonhuman 
cell lines with antisera raised to synthetic peptides corresponding to A4 and to two other domains of the APP. All three 
antisera recognized a 130 kDa polypeptide (APP-130) in immunoblots from all cell lines. In fibroblasts, an additional 
polypeptide of 228 kDa (APP-228) was recognized by the antiserum to A4. In immunoblots of two dimensional gels, 
APP-130 showed a pl  of 6.2, while APP-228 failed to focus in the pH range of 4.7 7.0. Sequential extractions of cells 
with buffer and with Triton X-100 indicate that APP-130 is extractable with nonionic detergents at high ionic strength, 
whereas 228 kDa APP is a cystolic component. Immunofluorescence staining is consistent with an intracellular perinu- 
clear and plasma membrane localization. It is concluded that APP-130 and APP-228 are two forms of the APP which 
result from extensive posttranslational modifications of a smaller original gene product. It is likely that APP undergoes 
similar posttranslational modifications in different cell types. 
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1. INTRODUCTION 
Deposition of amyloid in brain, associated with 
the formation of senile plaques and amyloid 
angiopathy, is a major pathological event in 
Alzheimer disease (AD), Down syndrome (DS) 
and, to a lesser extent, in normal aging [1]. This 
amyloid is distinct from that of other amyloidoses 
[2-6], and derives from a larger precursor protein 
for which at least three species of mRNA are ex- 
pressed as a result of alternative splicing [7-13]. 
Based on the cDNA-derived primary sequence, a
putative structure has been proposed which in- 
cludes an N-terminal signal sequence, three ex- 
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tracellular domains, a transmembrane region and a 
cytoplasmic C-terminal domain of 47 residues 
[7,14]. On the basis of this structure, it has been 
suggested that APP is a transmembrane 
glycosylated protein with features typical of a cell 
surface receptor or an adhesion molecule 
[7,14,15]. The major component of AD amyloid is 
a 42 residue polypeptide corresponding to amino 
acids 597-639 of the deduced APP sequence; its 
putative location comprises both transrnembrane 
and extracellular domains [7]. Evidence has also 
been obtained for a precursor-product relationship 
between APP and amyloid, as APP domains 
analogous to A4, along with the transmembrane 
and cytoplasmic domains, have been shown to ag- 
gregate and form amyloid fibrils under ap- 
propriate conditions [14]. 
Northern blot analysis indicates that APP is pre- 
sent in a variety of tissues [8,9,11,13]. However, 
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scarce and controversial information is available 
concerning size and subcellular location of APP in 
intact tissues or cells [16-18]. Some of the con- 
troversy may be due to attempts to identify APP in 
postmortem tissue in which proteins may have 
undergone autolysis. Thus we have tried to 
characterize APP in cultured cells. A 130 kDa 
polypeptide (APP-130) is consistently recognized 
in human cell lines by three antisera raised to syn- 
thetic polypeptides homologous to sequences span- 
ning residues 95 to 658 of the putative APP. In 
addition to APP-130, one antiserum also 
recognizes a 228 kDa polypeptide (APP-228) in 
human fibroblasts. Sequential extractions and im- 
munofluorescence experiments indicate that these 
two polypeptides reside in different cell compart- 
ments including nuclear, perinuclear and plasma 
membranes and the cytosol. This study has been 
presented in part [19]. 
2. MATERIALS AND METHODS 
(diluted 1:20) with the corresponding peptides (100ug pep- 
tide/ml) were done by gentle mixing overnight at 4°C followed 
by a brief centrifugation. 
2.4. Gel electrophoresis and immunoblotting 
Polypeptides were resolved in 8% polyacrylamide mini gels. 
Two-dimensional gel electrophoresis was carried out as de- 
scribed [20], using a pH range of 4.5-7.0 for the first dimension 
and a 8°7o polyacrylamide slab gel in the second. Polypeptides 
were electrotransferred to nitrocellulose [21] and the mem- 
branes blocked with 10% non-fat milk at 40°C for 1 h. Incuba- 
tions with primary antisera were done overnight at 4°C and 
with peroxidase-labeled goat anti-rabbit for 1 h at room 
temperature. Diaminobenzidine was used as chromogen. 
2.5. Immunofluorescence 
Fibroblasts grown on coverslips and cytospins of K-562 cells 
were fixed in 3070 formaldehyde for 20 min, followed by 7 min 
in acetone at - 20°C, or treated only with acetone. Incubations 
with primary and with fluorescein-labeled antibodies were for 
1 h at 37°C. Cells were examined and photographed in a Leitz 
Dialux microscope quipped with epifluorescence illumination. 
Photographic exposures of preparations stained with absorbed 
antisera were of similar length to the automatic exposure re- 
quired for the nonabsorbed antisera. 
2.1. Cell cultures 
Primary cultures of human fibroblasts were obtained from 
NIGMSH Human Genetic Cell Repository. Cultures were kept 
in a 7070 CO2 humidified incubator and fed with Dulbecco's 
modified Eagle's medium supplemented with 1007o fetal bovine 
serum and 1070 penicillin/streptomycin. K-562 cells, a con- 
tinuous chronic myelogenous leukemia cell line, and U937 cells, 
a histocytic lymphocytoma cell line, were obtained from ATCC 
and cultured as above in RPMI 1640 medium containing 10°70 
fetal bovine serum. Cos I cells, a monkey kidney cell line was 
kindly provided by Dr F.M. Rottman. 
2.2. Extraction of  cells 
All operations were done at 0-4°C. Confluent cultures of 
fibroblasts and Cos 1 cells were washed free of medium with 
PBS. Cells were scraped and homogenized in a ground glass 
homogenizer in l0 mM phosphate buffer, pH 7.0, 2.5 mM 
PMSF (buffer A). K-562 cells were pelleted at 1000 × g, washed 
in PBS and homogenized in buffer A. After centrifugation for 
60 min at 100000 × g, the cytosolic fraction was obtained and 
the pellet was homogenized in buffer A containing 1070 Triton 
X-100. After centrifugation at 20000 × g for 20 min, the Triton 
soluble fraction was removed and the pellet homogenized in 
buffer A containing 1°70 Triton X-100 and 0.6 M KCI. After 
centrifugation as above, the high ionic strength fraction was 
removed and the pellet dissolved in electrophoresis sample 
buffer. 
2.3. Antibodies 
Antisera were raised in rabbits to synthetic peptides cor- 
responding to amino acid sequences 638-658 (C5), 95-110 
(N77) and 597-638 (A4) deduced from the APP cDNA [7]. 
Peptide C5 was coupled to KLH and N77 to thyroglobulin, 
while A4 was injected uncoupled. Absorptions of the antisera 
3. RESULTS AND DISCUSSION 
In immunoblots of total homogenates of human 
fibroblasts, human myelogenous leukemia (K562), 
human histiocytic lymphocytoma cell line (U937) 
and monkey kidney cells (Cos I), all three antisera 
to the 597-638 (A4), 95-110 (N77) and 638-658 
(C5) APP amino acid regions, recognize a 
polypeptide showing a mobility of 130 kDa in 
SDS-PAGE (fig.l). The antiserum to the A4 
region recognized also a polypeptide migrating at 
228 kDa in fibroblasts and a set of less distinct 
bands of comparable size in K562 cells (fig. 1). Ab- 
sorption of the antisera with the synthetic peptides 
used as antigen, but not with synthetic peptides to 
other regions of APP, abolished the reaction 
(fig. 1). 
In immunoblots of fibroblasts extracts eparated 
by 2D-PAGE, APP-130 showed a pI of 6.2, while 
the APP-228 failed to focus in the pH range of 
4.7-7.0 (fig.2). Thus, these data show that three 
antisera to different domains of APP specifically 
recognize a polypeptide of 130 kDa, indicating 
that this polypeptide is a form of APP which is 
present in various cell types. The apparent size of 
this polypeptide is larger than the 78.6 kDa 
predicted from the derived sequence and the 
91.5 kDa polypeptide obtained in a cell-free 
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Fig.1. lmmunoblots of total cell extracts with antibodies t  
APP. Lanes: a, b, human fibroblasts; c-f, K562 cells; g, Cos 
1 cells; h, U937 cells. Antibodies us dwere: A4 (597-638 APP 
aa sequence) for lanes a,c and h; A4 (597-638 APP aa 
sequence) absorbed with corresponding peptide, lane b; N77 
(95-110 APP aa sequence), lane d; N77 (95-110 APP aa 
sequence) absorbed, lane e; C5 (638-658 APP aa sequence), 
lane f. A band of 130 kDa is present in all cell lines. A band of 
228 kDa or a series of bands of comparable size are evident in 
fibroblast and K562 cell preparations immunostained with the 
A4 antibody. Molecular masses are shown on the left (kDa). 
system [7,14]. This difference is consistent with 
APP  being glycosylated [7,14], and possibly being 
the protein core of  a heparan sulfate proteoglycan 
[15], since glycosylation is likely to result in a 
slower electrophoretic mobil ity. 
The identical size of  APP-130 in the cells ex- 
amined indicates that APP  undergoes the same 
posttranslat ional  processing, and possibly has the 
same location and funct ion in various cell types. 
APP-228,  which is consistently detected only in 
f ibroblasts, might represent a highly modif ied 
form of  APP .  
In order to gain insight into the subcellular 
local ization of  these polypeptides, f ibroblasts were 
fract ionated by sequential extractions with buffer 
and Tr i ton X-100 at low and high ionic strength 
(fig.3). APP-228 was extracted in hypotonic buf- 
fer, while APP-130 was recovered in the Triton ex- 
tract at high ionic strength. This analysis indicates 
that APP-228 is a cytosolic component  while 
APP-130 is associated with another component ,  
possibly membranes.  Thus in fibroblasts, there 
seem to be two forms of  APP  localized in different 
cell compartments.  
Fig.2. Immunoblots of human fibroblast extract after 
separation by two-dimensional gel e ectrophoresis. APP-130 
focus at pH 6.2 (arrow). On the right, a sample of th same 
extract run only in the second dimension (arrowhead). APP-228 
was not detected in the pH range 4.7-7.0. Only the area of 
interest is shown. Molecular masses are shown on the right 
(kDa). 
Immunof luorescence in cells fixed in for- 
maldehyde showed intracellular staining, that was 
more intense over the nucleus (fig.4), while in cells 
that were only permeabil ized with acetone, stain- 
ing was mostly perinuclear, both in fibroblasts and 
K562 cells (fig.5). In unfixed cytospin prepara- 
tions, K562 cells showed a light diffuse and strong 
patchy distribution of  the immunof luorescence 
228--  
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Fig.3. lmmunoblots of fibroblast fractions immunostained with 
A4. Lanes: a, total homogenate; b, buffer extract; c, Triton 
extract; d, Triton/KCl extract; e, insoluble. APP-228 is 
recovered with hypotonic buffer, while APP-130 is extracted 
with Triton at high ionic strength. These extractions are 
consistent with a cytosolic location of APP-228 and a possible 
association with membranes of APP-130. 
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Fig.4. Human fibroblasts fixed in paraformaldehyde. A, diffuse fluorescence is seen around the nucleus; B, at higher magnification 
the fluorescence is especially noticeable over and around the nucleus, suggesting that APP is located in the nuclear membrane and 
other perinuclear structures. A, N77 antibody, x 250; B, A4 antibody, x 400. 
O 
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Fig.5, K562 cells. In cells permeabilized with acetone (A) the immunofluorescence is especially prominent in structures immediately 
around or adjacent to the nucleus, while in unfixed cytospinned ceils (B) there is a diffuse, weak immunofluorescence with patches 
of more intense immunostaining. A, A4 antibody, x 200; B, A4 antibody, x 200. 
O 
Fig.6. Fibroblasts fixed with paraformaldehyde. No immunofluorescence is seen with the N77 antiserum absorbed with the appropriate 
peptide. A, Fluorescence, x 360; B, phase, x 360. 
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(fig.5). Staining was blocked by absorption with 
the relevant peptide (fig.6). Thus, the pattern of 
immunosta in ing we have observed, is consistent 
with the localization of the APP-130 in the nuclear 
and possibly other intraceUular membranes in- 
cluding, at least in K562 ceils, the plasma 
membrane.  
Our findings of a perinuclear immunolocal iza- 
t ion of APP  in fibroblasts and of a patchy 
distr ibut ion at the surface of K562 cells are similar 
to the localization in the nuclear envelope and 
plasma membrane reported in human muscle cells 
and rat neurons [16,22]. However, a definite 
localization should be provided by immunostain-  
ing at the lectron microscope. 
In a previous study, we demonstrated that the 
two antisera to synthetic peptides homologous to 
APP  sequences other than A4 used in this study 
immunosta in  deposits located around the core of 
the senile plaque, which is itself unstained [23]. 
Our f indings showing that the same antibodies 
recognize the APP ,  support he hypothesis that the 
processing of APP  leading to the deposition of A4 
occurs within the plaque, in the immediate vicinity 
of the core. 
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